



March 13, 2020

Press Release

SUZUKEN CO., LTD.

Hiromi Miyata, President and CEO

(Stock Code: 9987)

Securities Traded: First Sections of the Tokyo and Nagoya Stock Exchanges, and the Sapporo Securities Exchange

Contact: Shigeru Asano, Executive Vice President; Senior General Manager, Corporate Management Headquarters

Tel.: +81-52-961-2331

Notice Regarding the Start of Operation of an Investigational Drug Traceability System, "Cubixx® CT"

A system which takes backup of temperature records and corresponds to various temperature bands

Suzuken Co., Ltd. (hereinafter, "Company") announced that we will newly develop a traceability system for investigational drugs, "Cubixx® CT (Clinical Trial) (hereinafter, Cubixx CT)", and start operation sequentially at institutions including clinical trial sites.

The Company started to deploy a specialty drug traceability system called "Cubixx® System (hereinafter, Cubixx)" from FY 2017. Cubixx is a traceability system using an exclusive storage cabinet equipped with RFID and IoT technology. It enables real-time and automated inventory control, quality control, warehousing/delivery control, and security monitoring of individual drugs, especially high-priced drugs requiring temperature control. Currently, it is mainly adopted by regional core hospitals and specialized hospitals.

Strict quality control and handling procedures at various temperature zones are necessary for the control of investigational drugs to evaluate their efficacy and safety, and they also have to be recorded. The newly developed Cubixx CT is equipped with not only the functions of the conventional Cubixx but also new functions, such as backup of temperature records and setting of various temperature bands (15 to 25°C, 1 to 30°C, in addition to the conventional 2 to 8°C). We believe that, through this service, we can further contribute to resolving issues in investigational drug management and improving operational efficiency for people who handle investigational drugs such as pharmaceutical companies, contract research organizations for drug development, and clinical trial sites.

The Company group has been engaged in the business of clinical trial logistics since 2010, and we would like to propose a total traceability of investigational drugs by combining our functions and know-how cultivated through clinical trial logistics with Cubixx CT.

■ Main services provided by "Cubixx CT"

1. Automatic acquisition of records of temperature, inventory, and opening/closing of the storage cabinet
2. Strict quality and security control
3. Correspondence to various temperature bands (2 to 8°C, 15 to 25°C, 1 to 30°C, etc.)
4. Automation of inventory and warehousing/delivery control by RFID tags
5. Reduction of inspection cost by an integrated system of a storage cabinet and a temperature logger



- The start of operation
April 2020

The impact of this matter on business performance is expected to be minor, but it is considered to contribute to enhancing the corporate value of the Company group in the medium- to long-term. If timely disclosure becomes necessary in the future, such information will be promptly disclosed.

This is an English translation of a statement written initially in Japanese and is provided for reference purposes only. The Japanese original shall prevail in the event of any discrepancy between this document and the original.